Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities (2016 - 2026)

Anika Therapeutics has reported Total Current Liabilities over the past 17 years, most recently at $21.0 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 17.12% to $21.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.0 million through Mar 2026, up 17.12% year-over-year, with the annual reading at $21.9 million for FY2025, 6.0% down from the prior year.
  • Total Current Liabilities was $21.0 million for Q1 2026 at Anika Therapeutics, down from $21.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $31.1 million in Q4 2023 and troughed at $16.1 million in Q2 2025.
  • The 5-year median for Total Current Liabilities is $26.1 million (2024), against an average of $24.8 million.
  • Year-over-year, Total Current Liabilities plummeted 42.54% in 2022 and then rose 17.12% in 2026.
  • A 5-year view of Total Current Liabilities shows it stood at $27.9 million in 2022, then increased by 11.27% to $31.1 million in 2023, then fell by 24.96% to $23.3 million in 2024, then decreased by 6.0% to $21.9 million in 2025, then decreased by 4.3% to $21.0 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Total Current Liabilities are $21.0 million (Q1 2026), $21.9 million (Q4 2025), and $19.1 million (Q3 2025).